World Hepatitis Alliance
The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment
LONDON, ENGLAND / ACCESSWIRE / April 4, 2024 / The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.WHS logo
Policy makers, civil society members, representatives from the private sector, academics and other stakeholders will convene to deliberate and share updates on innovative approaches to increase access to testing, vaccination and treatment services for viral hepatitis. Deliberations will also focus on addressing stigma and discrimination and advocating for funding, with an aim for viral hepatitis elimination by 2030.
At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe. The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis. Around a quarter of people living with hepatitis B and C report they have not told their family (23%) or friends (25%) about their hepatitis.
Eliminating the stigma surrounding hepatitis through the introduction of policies and structural changes has been named as a key factor in hepatitis elimination by the World Health Organization (WHO).
On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report. It is the first consolidated report on viral hepatitis epidemiology, service coverage and product access, with improved data for action. With information from 187 countries, the report outlines regional perspectives and actionable steps to scale up interventions, emphasising the importance of leveraging lessons from the COVID-19 response. A standalone press release will be issued by WHO on 9 April.
About the World Hepatitis Summit
The World Hepatitis Summit is organised by the World Hepatitis Alliance, with the support of the Ministry of Health of Portugal and co-sponsored by WHO. Its mission is to support countries in meeting the targets needed to eliminate viral hepatitis. It is being held in Lisbon and virtually. More information: http://worldhepatitissummit.org/ and https://www.worldhepatitisalliance.org/.
About Viral Hepatitis
Viral hepatitis is inflammation of the liver caused by a virus. WHO says that the total deaths cause by viral hepatitis, including acute cases, cirrhosis and liver cancer, accounted for 1.1 million deaths globally in 2019. In total, over 350 million people in the world are living with viral hepatitis. Each year, over a million people lose their lives because of conditions related to acute hepatitis and chronic infection that cause liver cancer and cirrhosis.
Contact Information
James Gillies
Communications Contact
james.gillies@worldhepatitisalliance.org
00447932328287
Steve Shaw
Marketing Manager
steve.shaw@worldhepatitisalliance.org
SOURCE: World Hepatitis Alliance (WHA)
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom